Skip to main content
    • Aa
    • Aa
  • The International Journal of Neuropsychopharmacology, Volume 9, Issue 5
  • October 2006, pp. 603-605

Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder

  • S. Craig Risch (a1), Michael D. Horner (a2), Susan R. McGurk (a3), Simmy Palecko (a1), John S. Markowitz (a2), Ziad Nahas (a2) and C. Lindsay DeVane (a2)
  • DOI:
  • Published online: 01 October 2005

Donepezil, 5 mg/d for 6 wk then 10 mg/d for 6 wk, and placebo daily for 12 wk in a double-blind cross-over paradigm, was added to the therapeutic regimen of 13 patients with schizophrenia or schizoaffective disorders, clinically stable on atypical antipsychotic medications. Patients had varying degrees of depressive symptoms, ranging from no depression to clinically significant depression. There was no worsening or induction of depression in individual patients or the group as a whole. In addition there was a statistically significant antidepressant effect in the group as a whole during the donepezil condition and a clinically significant antidepressant effect in the patients with clinically significant depressive symptoms, although there were not enough depressed patients in the group to conclude that donepezil may have antidepressant effects. Thus, in this study, donepezil did not induce or worsen depressive symptoms in schizophrenic and schizoaffective disorder patients.

Corresponding author
UCSF Department of Psychiatry, 401 Parnassus Avenue Box F-0984, San Francisco, CA 94143-0984, USA. Tel.: (415) 476-7710 Fax: (415) 476-7320 E-mail:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *